Home Endocrinology & Hormones Estrogen/progestogen Receptor modulator Toremifene Citrate (NK 622) For research use only.

Toremifene Citrate (NK 622)

Synonyms: NSC 613680,NK 622 Citrate

Toremifene Citrate (NK 622, NSC 613680) is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.

Toremifene Citrate (NK 622) Chemical Structure

Toremifene Citrate (NK 622) Chemical Structure

CAS: 89778-27-8

Selleck's Toremifene Citrate (NK 622) has been cited by 8 Publications

2 Customer Reviews

Purity & Quality Control

Batch: Purity: 100%
100

Toremifene Citrate (NK 622) Related Products

Signaling Pathway

Estrogen/progestogen Receptor Signaling Pathways

Estrogen/progestogen Receptor Signaling Pathway

Choose Selective Estrogen/progestogen Receptor Inhibitors

Biological Activity

Description Toremifene Citrate (NK 622, NSC 613680) is an oral selective estrogen receptor modulator (SERM), used in the treatment of advanced breast cancer.
Targets
Estrogen receptor [1]
In vitro
In vitro Toremifene (7.5 mM) causes approximately 60% of the cells to exhibit morphologic characteristics typical of cells undergoing programmed death, or apoptosis in human breast cancer cells. Toremifene (5-10 mM) results in elevated levels of TRPM-2 and TGF beta 1 mRNAs in in vitro or in vivo grown tumor cells. Toremifene causes growth inhibition of estrogen-sensitive breast cancer cells by inducing some cells to undergo apoptosis and by inhibiting other cells from entering mitosis. [1] Toremifene induces a dose-dependent level of adducts that is lower than that observed for TAM. Toremifene significantly enhances endogenous DNA adduct formation. [2] Toremifene affects the cell turnover by inhibiting mitotic activity and modifying abundant spontaneous apoptosis in DMBA-induced rat mammary carcinoma. [3]
In Vivo
In vivo Toremifene, at the highest tested dose, increases the incidence of hepatocellular carcinomas in the DEN-initiated groups to a level one-third that observed with Tamoxifen administration to DEN-initiated rats. Toremifene increases the incidence of hypernephromas in previously DEN-initiated rats. [4] Toremifene results in aneuploidy in 50% of the cells examined and compared with the 85% level induced by Tamoxifen in female Sprague-Dawley rats. [5]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01214291 Withdrawn
Risk of Bone Fracture Occurrences
GTx|Ipsen
 March 2011 Phase 3
NCT00267553 Terminated
Breast Neoplasms|Neoplasms Hormone-Dependent
Intarcia Therapeutics
 November 2005 Phase 3
NCT00106691 Completed
Preneoplastic Conditions|Prostatic Intraepithelial Neoplasia
GTx
 January 2005 Phase 3

Chemical Information & Solubility

Molecular Weight 598.08 Formula

C32H36ClNO8
CAS No. 89778-27-8 SDF Download Toremifene Citrate (NK 622) SDF
Smiles CN(C)CCOC1=CC=C(C=C1)C(=C(CCCl)C2=CC=CC=C2)C3=CC=CC=C3.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 120 mg/mL ( (200.64 mM)； Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Toremifene Citrate (NK 622) | Toremifene Citrate (NK 622) ic50 | Toremifene Citrate (NK 622) price | Toremifene Citrate (NK 622) cost | Toremifene Citrate (NK 622) solubility dmso | Toremifene Citrate (NK 622) purchase | Toremifene Citrate (NK 622) manufacturer | Toremifene Citrate (NK 622) research buy | Toremifene Citrate (NK 622) order | Toremifene Citrate (NK 622) mouse | Toremifene Citrate (NK 622) chemical structure | Toremifene Citrate (NK 622) mw | Toremifene Citrate (NK 622) molecular weight | Toremifene Citrate (NK 622) datasheet | Toremifene Citrate (NK 622) supplier | Toremifene Citrate (NK 622) in vitro | Toremifene Citrate (NK 622) cell line | Toremifene Citrate (NK 622) concentration | Toremifene Citrate (NK 622) nmr